ConvaTec recalled 80,980 DuoDERM Extra Thin dressings on August 29, 2025, due to potential foreign matter contamination. The dressing is designed for dry to lightly exudating wounds and is suitable for use on sensitive areas. Patients should stop using the product immediately and follow the recall instructions provided by the manufacturer.
Wound dressing may have foreign matter on the product.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact ConvaTec, Inc or your healthcare provider for instructions. Notification method: Letter
The recalled product is DuoDERM Extra Thin dressings, with model numbers UDI-DI: 768455150922 and Lot: 3L04808. The dressings were distributed nationwide across the United States.
The wound dressing may contain foreign matter, posing a risk of infection or other complications. The contamination could potentially impact the healing process.
As of the recall date, there were no reported injuries or incidents associated with this product. The recall is precautionary.
Patients and healthcare providers should immediately stop using the DuoDERM dressings. Contact ConvaTec, Inc. or your healthcare provider for further instructions and follow the recall notification method, which includes a letter.
For more information, contact ConvaTec, Inc. through their official website or customer service number. Additional details are available on the FDA website.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.